Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Lots more details about the fallout from STAT’s John Wilkerson. Read more here.

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

Unseasonably high flu cases are leading to an uptick in visits to NSW emergency departments while COVID continues to increase ...

People with ties to Brownstone Institute have significant authority over access to vaccines and scientific research.